Amerigen, Stason in generic oral oncology products development agreement

As per the agreement, Stason will use its specialized containment facilities and formulation expertise to develop and manufacture products for Amerigen to commercialize it in the US and other territories.

As part of its effort, Stason received an up-front fee and is eligible for additional product-specific development milestones, plus manufacturing revenues and royalties on any commercialized products.

Amerigen Chief Business Officer Jonathan Embleton said they look forward to work with Stason to bring generic versions of some important critical care products to market and they are especially pleased to announce the concurrent filing of the first abbreviated new drug application (ANDA) from this collaboration.